Astragalus

Metadata

Approved Indications

Commission E (Germany)

• No Commission E monograph. Astragalus was not part of the German/European phytotherapy tradition at the time of Commission E evaluations.

ESCOP

• No ESCOP monograph for Astragalus membranaceus.

EMA/HMPC

• No HMPC assessment or monograph initiated. Astragalus membranaceus is not listed on the HMPC work program. The very limited number of HMPC monographs for TCM-origin herbs reflects regulatory challenges in bridging Eastern and Western herbal medicine frameworks.

European Pharmacopoeia

• Not included in the European Pharmacopoeia as of the 10th edition (2020), though the EP has been gradually adding TCM-origin monographs. Quality monographs (not therapeutic monographs) for some TCM herbs are being developed. [NEEDS-RESEARCH for 11th edition status]

Other Pharmacopoeias

• Chinese Pharmacopoeia: Listed as Huang Qi; official drug with multiple approved indications
• Japanese Pharmacopoeia (JP XVII, 2016): Listed
• Korean Pharmacopoeia: Listed
• US Pharmacopoeia: Dietary ingredient monograph available
• American Herbal Pharmacopoeia: Monograph published

Agreement/Disagreement

• Striking absence: Astragalus has robust pharmacopoeial recognition in East Asia and quality standards in the US, but ZERO regulatory recognition as a therapeutic agent in Europe. This reflects the EU framework’s structural difficulty in accommodating non-European traditional medicines rather than any judgment on the herb’s merit.

Conditions Treated

TCM Traditional Indications (Documented)

• “Tonifying Qi” — general vitality and immune enhancement
• Spleen Qi deficiency: fatigue, poor appetite, diarrhea
• Lung Qi deficiency: frequent colds, shortness of breath, spontaneous sweating
• Blood deficiency: pallor, dizziness (often combined with Angelica sinensis)
• Edema and fluid retention
• Wound healing (chronic non-healing ulcers)

Modern/Western Research Indications

• Immune support during chemotherapy (adjunctive)
• Upper respiratory tract infection prevention
• Cancer-related fatigue (emerging evidence)
• Chronic hepatitis (adjunctive, primarily Chinese studies)
• Diabetic nephropathy (adjunctive, primarily Chinese studies)
• Cardiovascular support (preclinical + limited clinical)
• Anti-aging / telomere support (through telomerase activation by cycloastragenol) [UNCERTAIN — primarily preclinical]

Mechanism of Action

Active Compounds

Immune Mechanisms

1. Macrophage activation: APS enhances macrophage phagocytosis, NO production, and cytokine secretion (TNF-alpha, IL-1, IL-6). Unique bidirectional effect: stimulates immune response in resting state but suppresses excessive pro-inflammatory signaling during active inflammation. [Source: PMC7105737]
2. Lymphocyte proliferation: Enhancement of both T-cell and B-cell proliferation
3. NK cell activation: Increased natural killer cell cytotoxicity
4. Cytokine modulation: Pro-inflammatory cytokine release in absence of infection; anti-inflammatory during active inflammatory states (bidirectional immunomodulation similar to elderberry)
5. Immunoglobulin stimulation: Enhanced secretion of IgA, IgG, IgM
6. Dendritic cell maturation: APS promotes dendritic cell maturation and antigen-presenting function
7. Complement activation: Enhancement of complement system activity

Adaptogenic Mechanisms

• HPA axis modulation: Regulation of cortisol and ACTH levels under stress [UNCERTAIN — primarily animal data]
• Antioxidant defense: Upregulation of SOD, catalase, and glutathione peroxidase
• Telomerase activation: Cycloastragenol activates telomerase in human T-cells (basis for TA-65 supplement), potentially extending immune cell lifespan [UNCERTAIN — clinical relevance debated]

Clinical Evidence Summary

Western-Quality RCTs (Limited)

Cancer-Related Fatigue Meta-Analysis (Sheng et al., 2025)

• Systematic review and meta-analysis of RCTs
• Concluded: “Current evidence is supportive of efficacy of Astragalus membranaceus in patients with cancer-related fatigue and quality of life”
• BUT: “Due to small and low-quality literature and lack of uniformity in cancer type and treatment modalities, there is currently insufficient evidence to provide strong support for clinical use”
• [Source: Sage Journals, DOI: 10.1177/15347354241313344]

Evidence Quality Assessment

• The vast majority of clinical studies are published in Chinese-language journals, often with methodological limitations (inadequate blinding, unclear randomization, small sample sizes)
• English-language RCTs meeting Western standards are very few
• Preclinical evidence (in vitro and animal studies) is extensive and strong
• The translation gap between preclinical promise and clinical validation is the central challenge

European vs. US/Anglophone Consensus

Safety Profile

Contraindications

• Autoimmune disease: As with all immunomodulators, theoretical concern about stimulating autoimmune pathways. More relevant for astragalus than for some other herbs due to its documented immune-enhancing effects. [Source: WebMD, NCCIH]
• Organ transplant recipients: Contraindicated due to risk of antagonizing immunosuppressive therapy
• Active infections with high fever: Some TCM traditions caution against using “tonifying” herbs during acute febrile illness

Drug Interactions

• Immunosuppressants (cyclosporine, tacrolimus, mycophenolate): Theoretical antagonism. Most clinically significant interaction.
• Lithium: Astragalus may have diuretic effects; could alter lithium levels
• Anticoagulants: Some astragalus saponins have mild antiplatelet activity [UNCERTAIN]
• Diabetes medications: May have additive blood sugar-lowering effects
• Overall: Drug interaction risk is LOW-MODERATE

Side Effects

• Very well tolerated. Doses up to 60 g/day for up to 4 months reported without adverse effects in clinical studies. [Source: WebMD]
• Occasional: Mild gastrointestinal symptoms (bloating, diarrhea)
• No significant hepatotoxicity or nephrotoxicity signals
• Injection forms (used in Chinese hospitals): Higher risk of adverse reactions including allergic responses; not relevant to oral supplementation

Pregnancy/Lactation

• Pregnancy: Insufficient human data. Some animal research suggests potential fetal toxicity. NOT recommended during pregnancy as a precaution. [Source: NCCIH]
• Lactation: Traditional TCM use during postpartum recovery, but insufficient Western safety data. Consult healthcare provider.

Clinical Dosage

Dried Root (Traditional TCM)

• Decoction: 9-30 g dried root slices simmered for 30-45 minutes (standard TCM dose)
• Higher doses: Up to 60 g in some TCM protocols (e.g., Bu Zhong Yi Qi Tang formula)

Standardized Extracts

• Powdered extract: 250-500 mg, 1-2 times daily (standardized to astragalosides or polysaccharide content)
• APS (Astragalus polysaccharide): 250-500 mg daily in supplement form
• Astragaloside IV: Specific dosing varies by standardization

Specialized Products

• TA-65 (T.A. Sciences): Cycloastragenol extract; 8 mg capsules for telomere support. Very expensive. Clinical evidence limited. [UNCERTAIN — single-ingredient telomere claims controversial]
• AstragalinTM: Standardized polysaccharide extract used in some clinical studies

Duration

• TCM tradition supports long-term use (weeks to months) as a tonic
• No upper duration limit established in safety studies, but periodic breaks are traditionally recommended

Sources

• McCulloch M et al. “Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis.” J Clin Oncol. 2006;24(3):419-430.
• Li X et al. “A Review of the Pharmacological Action of Astragalus Polysaccharide.” Fundam Clin Pharmacol. 2020;34(4):459-470. (PMC7105737)
• Astragalus membranaceus Monograph. Alternative Medicine Review. 2003;8(1):72-77. (Pubmed 12611564)
• Sheng X et al. “Efficacy of Astragalus Membranaceus for Cancer-Related Fatigue.” Integr Cancer Ther. 2025;24. (DOI: 10.1177/15347354241313344)
• NCCIH: “Astragalus: Usefulness and Safety” (https://www.nccih.nih.gov/health/astragalus)
• EMA Inventory of herbal substances for assessment (Astragalus not listed)
• Auyeung KK et al. “Astragalus membranaceus: A Review of its Protection Against Inflammation and Gastrointestinal Cancers.” Am J Chin Med. 2016;44(1):1-22.

Connections

• Eleuthero: Both are adaptogenic herbs; Eleuthero has EU recognition while Astragalus does not, despite comparable evidence levels
• Rhodiola: Both classified as adaptogens; Rhodiola has HMPC monograph for stress/fatigue
• Echinacea: Both are immunomodulators but from completely different traditions; Echinacea is the Western equivalent of Astragalus in terms of “go-to immune herb”